Member Info for Doc3

I will try and add something that may have meaning.

On Tuesday the R&D director is speaking at ADC conference. Chief commercial officer is also there.

AstraZeneca have a big presence at that conference.

Please stop.

I actually think this company is significantly undervalued but constant updates with no basis in fact are exhausting and don’t help.

One other point.

One of the first things the new leadership did was get SOC 2 compliance. I don’t understand this. But I think it’s an audit about data handling.

I assume may be important for pharma companies. Especially if they are sending pt samples to the lab.

May be nothing. May be important.

This is that recent statement.

https://www.sciencedirect.com/science/article/abs/pii/S0959804925009360

Behind paywall but broadly

20% of clinician/scientists think Parsortix is the right ctc platform to use clinically now

40% think it’s the future (out of 30).

The difference is cell search which is used now but they seem to think has less future role. Cellsearch depends on antibodies. Parsortix doesn’t, it’s epitope independent.

Parsortix is actually brilliantly unique. I’m not sure you would ever get to it iteratively. It makes it very versatile. AN didn’t design it but he did spot it..

Of note in the BG they also have a Parsortix plus (PX+) machine they have tested but not released. I think it just enriches, you can’t stain on it. But it’s much quicker and it can then integrate with other systems, such as Illumina NGS.

There is a lot of positive in the company. Apart from finances.

I have no idea how this may play out. There isn’t much value left to lose. But I would point out

1 Science. Regardless of the business the science is sound. I do think AN was right on the latter. It really could be a big market opportunity. A concensus statement on CTCs published recently suggested 40% of clinicians asked (out of 30) thought Parsortix was the future of clinical ctc liquid biopsy. Book chapters, papers all back it.

2 AstraZeneca. The assay development was successful, that isn’t disputed. Trinity delta in January did say that any further deal was likely to occur in late 2025. If it was a phase iii trial it could be 15 million.

3 Both the Chair and CEO have signed deals with azn before in other companies.

4 Finance. Yes that it existentially poor. But that isn’t unusual in biotech, I think they call it the valley of death between clear science and commercialisation. If they have any chance it’s with the team now in place.

5 Leadership. Again I think AN was basically right about the tech. He’s gone. The whole company has erased him (Angle was AN, the name from him). That does allow a clean break and may change ongoing negotiations.

I have no idea. But there might be opportunity here. There’s little left to loose.

Website changed.

Kim Oreskovic also listed as senior advisor.

I’ve noticed that the chief scientific officer Karen Millar has disappeared from the website.

It will do more than hurt? It will wipe out.

I’m still not really sure why the company choose to announce it so ahead.

Appreciate this is all a desperate situation.

But I noticed that Angle has gone to trouble to get SOC 2 compliance. I think it’s important for patient details etc.

I also dimly remember Trinty Delta saying it would be end 2025 before any further deals with AZN.

I note the new ceo worked with AZN in Saga diagnostics.

The outgoing board did continue to reiterate the line that funds could come from various sources. Yes some was just hype but it must have had some basis in reality.

It’s probably all circumstantial but it is a kernel of hope.

Could that a pharma deal for say 5 million land before raise?